Brind.

Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.

Steady: 1 in the last 7 days Updated monday

The latest in this situation

  1. Roche Pharma Vietnam partners with the Bright Future Fund, which is led by Nguyen Thi Xuyen.
  2. Novartis funds Phase 2 trial work with Monte Rosa Therapeutics for a VAV1-targeted drug.

How it started

6 reports, 4 independent, last reported Sep 13. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.

Who's involved

What this event is mainly about
Monte Rosa TherapeuticsHoffmann-La RocheNovartis

How it developed

Newest first. Tap a step to see who reported it.
  1. Novartis funds Phase 2 trial work with Monte Rosa Therapeutics for a VAV1-targeted drug.1 source
  2. CEO Jack Roche emphasized portfolio and partnerships.Sub-event
  3. Monte Rosa Therapeutics secured global licensing with Novartis and a collaboration with Roche.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • insidermonkey.com
  • manilatimes.net
  • GlobeNewswireMonte Rosa Therapeutics to Participate in Upcoming Investor Conferences BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company
  • GlobeNewswireMonte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential
  • Clinical Trials ArenaMonte Rosa doses first subjects in trial of MRT-8102 for inflammatory conditions Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degr
1 more outlet ran the same wire story